Its activation, primarily through binding of the ligand growth arrest-specific 6 (Gas6), triggers downstream signaling pathways including PI3K/AKT, MAPK, and NF-κB, which collectively contribute to tumor aggressiveness and poor clinical outcomes [14]. The gene discussed is GAS6; the disease is neoplasm.